Sinemet in ALS and PLS

Study Purpose:

Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa (Sinemet) to attempt to improve spasticity in ALS and PLS patients. However, data on the efficacy of carbidopa/levodopa is limited. Given the limited data and potential to improve the quality of life of these patients, the effectiveness of carbidopa-levodopa in ALS and PLS patients with severe spasticity should be studied. The investigators hypothesis is that administration of carbidopa-levodopa will improve spasticity in ALS and PLS patients.

Study Status:

Not recruiting

Disease:

Amyotrophic Lateral Sclerosis , Motor Neuron Disease

Study Type:

Interventional

Type of Intervention:

Drug

Intervention Name:

carbidopa-levodopa, Placebo Oral Tablet

Placebo:

Yes

Phase:

Phase 1

Study Chair(s)/Principal Investigator(s):

Timothy M Miller, MD, PhD, Washington University School of Medicine

Clinicaltrials.gov ID:

NCT03929068

Neals Affiliated?

No

Coordinating Center Contact Information